1 min read
Add as a preferred source on GoogleAcadia Raises DAYBUE 2026 Sales Outlook to $505 Million to $520 Million
DAYBUE generated record third-quarter net sales of $140 million, and Acadia reaffirmed its goal of $700 million in sales by the end of 2028.
Acadia Pharmaceuticals Inc. raised its 2026 DAYBUE sales outlook to $505 million to $520 million and reaffirmed confidence in reaching $700 million in sales by the end of 2028, as DAYBUE generated record third-quarter net sales of $140 million.
Acadia recorded $342 million in total revenue for the quarter. NUPLAZID contributed $202 million in net sales.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.